Currently Viewing:
ACOG Annual Clinical and Scientific Meeting
Currently Reading
Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer
July 11, 2018
Dr John Schorge Discusses Prevention Methods in Ovarian Cancer
June 30, 2018
Dr Jamie Bakkum-Gamez on Developing an Early Detection Test for Endometrial Cancer
June 28, 2018
Rear Admiral Dr Wanda Barfield on Perinatal Morbidity and Mortality
June 25, 2018
Dr Haywood Brown on the Alliance for Innovation in Maternal Health
June 23, 2018
Dr Mary Norine Walsh on Who Is at High Risk for Peripartum Cardiomyopathy
June 21, 2018
Dr John Schorge Discusses Disparities in Care of Endometrial Cancer
June 19, 2018
Dr Jamie Bakkum-Gamez Discusses the Importance of Genetic Testing After Ovarian Cancer Diagnosis
June 16, 2018
Dr Curtis Lowery on How His Practice Uses Technology to Benefit Patients
June 15, 2018
Rear Admiral Dr Wanda Barfield Provides an Overview of the Biggest Challenges Neonatologists Face
June 13, 2018
Dr Mary Norine Walsh Discusses Risks for Pregnant Women With Hypertension
May 30, 2018
Dr Curtis Lowery: The ANGELS Program and How It Benefits Patients
May 29, 2018
Dr Curtis Lowery: How Technology Can Lower Costs for OB/GYN Patients
May 18, 2018
Former Ambassador Nancy Brinker on the Future of the Susan G. Komen Foundation
May 17, 2018
Dr Mary Norine Walsh on the Rise of Maternal Mortality in the United States
May 16, 2018
Dr Haywood Brown on the Importance of Postpartum Follow-Up
May 15, 2018
Dr John Schorge on Palliative Care Practices in Ovarian Cancer
April 30, 2018
Dr Jamie Bakkum-Gamez Discusses the Importance of Enhanced Recovery Pathways
April 30, 2018
USPSTF Session Brings Lively Comments on Link Between Ratings, Coverage
April 30, 2018

Dr John Schorge on Neoadjuvant Chemotherapy Treatment in Advanced Ovarian Cancer

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.


John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses the findings of his study on neoadjuvant chemotherapy treatment of patients with advanced ovarian cancer.

Transcript

What were the findings of your study that investigated the delivery of neoadjuvant chemotherapy to women with advanced ovarian cancer?

One of the conundrums and controversies in the field is people that present with ovarian cancer– two-thirds of the time it's fairly advanced. Whether to start with surgery first or chemotherapy first has been the dilemma. 

Historically, people have started with surgery first, and yet over the last decade or so there's been a lot more evidence that starting with chemotherapy– such as neoadjuvant chemotherapy, which means chemo first– seems to work out just as well in the long run in many cases. 

Part of our work was looking at that trend and then determining that as an interval operation– which means halfway through the chemotherapy– if you're able to do a minimally invasive operation, like a standard laparoscopy, people have similar outcomes to open surgery, and a lot fewer side effects and a lot less complication risk.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!